When It Comes to the Treatment of Infantile Spasms

Time to treatment initiation and effective dosing can have a significant and lasting impact

Pyros Pharmaceuticals is developing enhanced specialty pharmaceuticals for rare diseases

At Pyros, we're focused on setting a new standard in healthcare, starting with patients suffering from infantile spasms. We're taking this opportunity to lift up families and support them in treating this severe, rare disease.

Michael Smith

Chief Executive Officer

February 15, 2024

Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP™ (vigabatrin oral solution)

Read more